Hummingbird Bioscience

Privately held: no public share price · Singapore

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
Phase 1/2
HER3Antibody–drug conjugate
Non-Small Cell Lung Cancer
Phase 1/2
HER3Monoclonal antibody
Non-Small Cell Lung Cancer

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
July 2027 (1)
ENV-501Phase 1/2Melanoma (Skin), Non Small Cell Lung Cancer, Breast Cancer
Est. primary completion 2027-07 · NCT06956690 · CT.gov ↗
What to watch
December 2027 (1)
NezutatugPhase 1/2Advanced or Metastatic Squamous Non-Small Cell Lung Cancer, Advanced Head and Neck Squamous Cell Carcinoma …
Est. primary completion 2027-12-01 · NCT05910827 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.